secondary efficacy endpoints

Related by string. secondary efficacy endpoint * Secon dary . SECONDARY . Secondary : Secondary Offering . Secondary School . Secondary Schools . Lasalle Secondary School / Efficacy . EFFICACY : primary efficacy endpoint . antimicrobial efficacy . preclinical efficacy / Endpoints . EndPoint . Endpoint : Secondary endpoints include . video conferencing endpoints . Secondary endpoints included * *

Related by context. Frequent words. (Click for all words.) 81 secondary endpoints 79 efficacy endpoints 76 primary endpoints 75 secondary endpoint 73 primary endpoint 72 composite endpoint 71 primary efficacy endpoint 70 clinical endpoints 69 Secondary endpoints 65 elagolix 65 pharmacodynamic 65 bosentan 65 Secondary endpoints included 65 evaluable 64 dose limiting toxicities 63 evaluable patients 63 tolerability 63 non inferiority 63 cardiovascular morbidity 62 Phase 2b study 62 dosing regimens 62 HbA1c levels 62 placebo controlled trials 62 HGS ETR1 62 Azixa 61 demonstrated statistically significant 61 phase IIb 61 peginterferon 61 Phase 2a trial 60 Zerenex 60 Secondary endpoints include 60 limiting toxicity 60 Phase 1b 60 ACTEMRA 60 free survival PFS 60 Phase Ib 60 clinically meaningful 60 adalimumab 60 sustained virologic response 60 monotherapy 59 mg BID 59 plus ribavirin 59 treatment emergent adverse 59 sapacitabine 59 mg dose 59 tolerated dose MTD 59 achieve statistical significance 59 Phase 2a clinical 59 chemoradiation 59 LEVADEX 59 Welchol 58 Phase IIa trial 58 Phase 2a 58 INCB# [002] 58 Phase IIa clinical 58 comorbid conditions 58 tolerability profile 58 fasting plasma glucose 58 endpoints 58 events AEs 58 LymphoStat B 58 multicenter randomized double 58 FOLOTYN 58 sitagliptin 58 laboratory abnormalities 58 febrile neutropenia 58 statistical significance 58 CoFactor 58 efficacy 58 RECIST criteria 58 pramipexole 58 denufosol 58 Phase 2b clinical 58 bortezomib 58 COPAXONE R 58 eculizumab 57 dasatinib 57 dosing schedules 57 MGCD# [002] 57 PF # [001] 57 Zenvia 57 pharmacokinetic profile 57 sunitinib 57 lamotrigine 57 phase 2a 57 AZD# 57 statistically significant improvement 57 mg doses 57 pharmacokinetic 57 Endpoints 57 DSMB 57 liver metastases 57 antitumor activity 57 picoplatin 57 azacitidine 57 Phase IIb clinical 57 RCTs 57 unblinded 57 tiotropium 57 telbivudine 57 Serdaxin

Back to home page